1. Introduction {#sec1}
===============

Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections are common worldwide ([@bib22]), but their epidemiologies vary globally ([@bib18]; [@bib33]; [@bib35]). HSV-1 is usually acquired orally, though evidence from Europe, North America, and Asia suggests increasing sexual transmission via oral sex ([@bib8]; [@bib18]; [@bib23]; [@bib36]). Meanwhile, HSV-2 is predominantly acquired sexually, drawing an intriguing epidemiology that shows strong overlap with HIV epidemiology ([@bib1]; [@bib19]; [@bib20]; [@bib29]; [@bib30]).

The viruses are closely-related antigenically posing a question about the possibility of a biological or an immunological interaction between the two infections---specifically, whether exposure to HSV-1, normally occurring in childhood ([@bib18]; [@bib33]), could be protective against HSV-2 infection, normally occurring only after sexual debut ([@bib33]; [@bib35]). Nonetheless, the viruses generally infect two different sites, oral versus genital ([@bib8]; [@bib17]), and thus, have different biological niches, with possibly varying immune responses ([@bib34]). Such compartmentalization may reduce the potential for an interaction ([@bib21]). Evolutionarily too, the viruses may have evolved to escape any cross protection to survive in human circulation, more so for HSV-2, as it is typically acquired in adulthood, after HSV-1 acquisition ([@bib21]).

Existing evidence on the HSV-1/2 association remains inconclusive ([@bib21]). Pooled results of prospective studies suggest a trend of lower risk of HSV-2 infection with prior exposure to HSV-1, however, not statistically significant ([@bib21]). Meanwhile, pooled results of cross-sectional studies suggest a higher risk of HSV-2 infection with prior exposure to HSV-1 in low sexual risk populations and in Europe, but no association in high sexual risk populations and in the United States ([@bib21]). Difficulty of adjusting for confounding factors, such as different risk behaviors and demographic and socio-economic factors; and the fact that some factors could be effect-modifiers as opposed to simple confounders, may explain, in part, the conflicting evidence ([@bib21]). Regardless, it remains unclear whether such an association exists between the two infections ([@bib21]).

Against this background, and thanks to the opportune availability of an existing multi-national cross-sectional individual-level database ([@bib11]; [@bib25], [@bib26]), we assessed the epidemiological evidence for an HSV-1/2 association.

2. Methods {#sec2}
==========

A database of HSV-1/2 serological testing results was assembled by merging databases of a series of seroprevalence studies ([@bib11]; [@bib25], [@bib26]). These studies were conducted on samples of men blood donors ≥18 years of age and residing in Qatar, but from different origin countries including: Egypt (N = 358), India (N = 325), Iran (N = 113), Iraq (N = 11), Jordan (N = 200), Lebanon (N = 118), Pakistan (N = 200), Palestine (N = 200), Philippines (N = 120), Qatar (N = 400), Sudan (N = 129), Syria (N = 200), and Yemen (N = 148). The original data was collected from a blood donor center that catered to men, thus the blood specimens and the data originated from men. The non-Qatari expatriates are primarily recent arrivals and short-term residents in Qatar, having spent the majority of their lifetime in their origin countries---their HSV-1/2 seroprevalence should more represent the exposure risk in their home countries, rather than in Qatar ([@bib11]; [@bib26]). The total sample size of the merged database was 2522. Besides serological results, the database included very basic socio-demographic variables, only age and nationality.

All HSV serological testing was conducted on existing anonymized blood specimens that were drawn (formerly for other studies ([@bib2]; [@bib3]; [@bib4]; [@bib24]) at Hamad Medical Corporation, Doha, Qatar, between June 2013 and June 2016. Approval for the research was obtained by the appropriate ethic boards at Hamad Medical Corporation (\#13204/13), Qatar University (\#QUST--CHS--SPR-2017-12), and Weill Cornell Medicine-Qatar (\#16-00012).

HSV-1 serology testing was implemented using the HerpeSelect® 1 enzyme linked immunosorbent assay (ELISA) kit (Cat. No. EL0910G-5, Focus Diagnostics, USA) ([@bib13]). For HSV-2 serology, and in consideration of published limitations of false sero-positivity in ELISA tests ([@bib6]), a two-test algorithm was incorporated by first using the HerpeSelect® 2 ELISA kit (Cat. No. EL0910G-5, Focus Diagnostics, USA) ([@bib14]) to test the sera, and then confirming all positive or equivocal results using the Euroline-Western Blot assay (Cat. No. DY 2531-2401-1 G, Euroimmun Laboratory, Germany) ([@bib12]). All testing results were analyzed following manufacturers' instructions ([@bib12]; [@bib13], [@bib14]).

Further details on these seroprevalence studies and laboratory methods are found in previous publications ([@bib5]; [@bib11]; [@bib25], [@bib26], [@bib27]).

The main analysis in this study assessed the HSV-1/2 association accounting for age and income level of country of origin. Country income was included as a covariate in view of existing evidence for an association between HSV-1 infection and socio-economic status ([@bib9]; [@bib33])---please note the high heterogeneity in the income level between the 13 origin countries represented in this study. For confirmation of results, sensitivity analyses were also conducted to assess the association between these herpes viruses adjusting for age and either country of origin or immigrant status (Qatari national vs. expatriate).

For statistical analysis, age was stratified into eight groups: ≤24, 25--29, 30--34, 35--39, 40--44, 45--49, 50--54, ≥55. Country of origin was stratified into four gross domestic product (GDP) categories per the World Bank classification ([@bib37]): low income, lower-middle income, upper-middle income, and high income countries. Sample characteristics were summarized using frequency distributions. Univariable and multivariable logistic regressions were conducted to assess the HSV-1/2 association. Unadjusted and adjusted odds ratios (OR), along with their respective 95% confidence intervals (CI), were reported. Significance was defined at α = 0.05. All analyses were performed using IBM-SPSS version 24.0.

3. Results {#sec3}
==========

Serological testing for HSV-1/2 was performed on 2522 specimens. Sample characteristics are summarized in [Table 1](#tbl1){ref-type="table"}. Sero-positivity for HSV-1 and HSV-2 was identified in 2053 (81.5%) and 87 (3.5%) specimens, respectively. Median age of the individuals in this sample was 37 years (ranging between 18 and 88 years). Majority of the sample originated from lower-middle income countries (52.8%; from Egypt, India, Pakistan, Palestine, Philippines, and Sudan), followed by upper-middle income countries (17.5%; from Iran, Iraq, Jordan, and Lebanon), then by a high income country (15.9%; from Qatar), and lastly by low income countries (13.8%; Syria and Yemen).Table 1Sample characteristics of the merged database of the series of seroprevalence studies ([@bib11]; [@bib25], [@bib26]). Univariable and multivariable logistic regressions assessing the epidemiological association between HSV-1 and HSV-2 infections. Unadjusted and adjusted odds ratios (OR and aOR, respectively) of HSV-2 infection, along with the respective 95% confidence intervals (CI), were reported.Table 1Sample CharacteristicsUnivariable AnalysisMultivariable AnalysisN (%)OR (95% CI)P-valueaOR (95% CI)P-value**HSV-2**[@](#tbl1fnatsign){ref-type="table-fn"} No2427 (96.2) Yes87 (3.5) Missing8[@](#tbl1fnatsign){ref-type="table-fn"}**HSV-1**[\#](#tbl1fnhash){ref-type="table-fn"} No465 (18.5)Ref Yes2053 (81.5)0.71 (0.43--1.17)0.1720.51 (0.30--0.87)0.013 Missing4[\#](#tbl1fnhash){ref-type="table-fn"}**Age** ≤ 24272 (10.8)Ref 25--29351 (13.9)1.94 (0.37--10.06)0.4322.09 (0.40--10.86)0.383 30--34427 (16.9)4.56 (1.03--20.24)0.0465.50 (1.23--24.52)0.025 35--39416 (16.5)4.00 (0.89--18.01)0.0714.85 (1.07--21.99)0.041 40--44373 (14.8)5.24 (1.18--23.25)0.0296.38 (1.43--28.52)0.015 45--49298 (11.8)4.67 (1.01--21.5)0.0485.52 (1.19--25.70)0.029 50--54203 (8.1)6.94 (1.5--32.05)0.0137.97 (1.70--37.30)0.008 ≥ 55180 (7.1)16.75 (3.86--72.61)\<0.00119.28 (4.37--85.11)\<0.001 Missing2**Gross Domestic Product**[\*](#tbl1fnlowast){ref-type="table-fn"} Low income countries348 (13.8)RefRef Lower-middle income countries1332 (52.8)1.81 (0.76--4.30)0.1791.61 (0.67--3.86)0.288 Upper-middle income countries442 (17.5)1.59 (0.59--4.29)0.3561.28 (0.47--3.48)0.627 High income countries400 (15.9)4.30 (1.76--10.51)0.0013.39 (1.36--8.41)0.009[^1][^2][^3]

Results from the univariable and multivariable logistic regressions assessing the HSV-1/2 association are reported in [Table 1](#tbl1){ref-type="table"}. Univariable analysis indicated no statistically significant association, and estimated an unadjusted OR of HSV-2 infection of 0.71 (95% CI 0.43--1.17; p-value 0.172). Higher odds of HSV-2 infection were estimated with increasing age and increasing country income level. Adjusting for age and country income level, a significant negative HSV-1/2 association was observed, with an adjusted OR of HSV-2 infection of 0.51 (95% CI 0.30--0.87; p-value 0.013).

A significant negative HSV-1/2 association remained in both sensitivity analyses. An adjusted OR was estimated at 0.53 (95% CI 0.30--0.94; p-value 0.030), when adjusting for age and country of origin, and at 0.49 (95% CI 0.20--0.83; p-value 0.008), when adjusting for age and immigrant status.

4. Discussion {#sec4}
=============

Using a large multi-national database of HSV-1/2 serological testing, we investigated the existence of an association between the two infections. Results indicated lower odds of HSV-2 infection with HSV-1 sero-positivity. This finding, based on cross-sectional data, contrasts with the pooled results of earlier cross-sectional studies that identified a higher odds of HSV-2 infection (in low sexual risk populations and in Europe), or no association (in high sexual risk populations and in the United States) ([@bib21]). However, this finding agrees with the pooled result of prospective studies ([@bib21]), lends credence to the conclusion that the positive HSV-1/2 association found in cross-sectional studies could be erroneous due to confounding ([@bib21]), and supports the higher quality prospective evidence suggesting a protective effect for HSV-1 exposure against HSV-2 acquisition ([@bib21]). This finding indicates the need to investigate and elucidate the immunological mechanism(s) that may explain such an interaction.

Although an HSV-1/2 interaction could possibly be bidirectional ([@bib21]), the cross-sectional design of our study cannot distinguish the direction of the interaction. Although the timing of HSV-1 or HSV-2 infection is unknown in our study, it is unlikely that the observed protective effect could be reversed, meaning HSV-2 infection protecting against HSV-1 infection. While in Western countries there is considerable HSV-1 incidence beyond childhood ([@bib7]; [@bib8]; [@bib15]; [@bib23]; [@bib28]; [@bib31]; [@bib32]), in the Middle East and North Africa the vast majority of HSV-1 incidence occurs during childhood ([@bib10]; [@bib26])---it will be rare for HSV-2 infection to precede HSV-1 infection in the Middle East and North Africa.

This study has limitations. The evidence for a protective effect cannot be regarded as definitive epidemiological evidence. The analyzed database is cross-sectional in nature, and thus cannot capture the temporal trend in exposure. The negative HSV-1/2 association was statistically significant only after adjustment for confounders, but not prior to adjustment. The adjustment was further implemented only for limited number of potential confounders, as available in the database---it was not possible to control for other potential confounders such as sexual risk behavior.

The database included only men donors and of specific age range between 18 and 88 years and median of 37 years---the identified association may not be generalizable to women or other age groups. The reported HSV-1/2 association among blood donors may not reflect the wider and general population. The observed association may not also be generalizable to individuals not eligible as blood donors, such as those HIV seropositive. Demographic information collected from the blood donors were recorded anonymously, and thus over time some of the participants may have contributed more than once.

Though the sample size was large, HSV-1 seroprevalence was high (\>80%) and HSV-2 seroprevalence was low (\<5%), affecting the statistical power of the study, as evident in the broad confidence intervals. Quality and validated commercial assays were used for HSV-1/2 serological testing, but existing evidence suggests potential variation in assay performance by global population ([@bib6]), thereby potentially affecting our results.

Concluding, HSV-1/2 infections are of growing interest with ongoing efforts to develop vaccines to control their transmission ([@bib16]). This study identified a negative association between these herpes infections, suggestive of a protective effect for HSV-1 sero-positivity against HSV-2 acquisition. This finding supports earlier pooled but inconclusive evidence from prospective studies, yet contrasts with pooled findings of cross-sectional studies. This finding also attests to a possibly strong antigenic link between both infections, thereby supporting the concept of developing a dually-effective vaccine against both viruses.
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The following is the supplementary data related to this article:DataData

[^1]: All four specimens were equivocal.

[^2]: Five specimens were equivocal and three specimens had insufficient sera for confirmatory testing.

[^3]: As Per the World Bank classification ([@bib37]): low income countries include Syria and Yemen; lower-middle income countries include Egypt, India, Pakistan, Palestine, Philippines, and Sudan; upper-middle income countries include Iran, Iraq, Jordan, and Lebanon; high-income countries include Qatar.
